Business description
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets five hematology/oncology drugs, and expects an FDA decision on another hematology drug later this year. Additionally, Spectrum's pipeline includes three drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.
Management board & Supervisory board
| CEO |
| Joseph Turgeon |
| Management board |
| Kurt Gustafson, Francois Lebel, Keith M. McGahan, Thomas J. Riga |
| Supervisory board |
| William L. Ashton, Bernice R. Welles, Dolatrai M. Vyas, Jeffrey L. Vacirca, Joseph W. Turgeon, Nora Brennan, Seth H.Z. Fischer |
Company data
| Name: |
Spectrum Pharmaceuticals Inc. |
| Address: |
11500 S. Eastern Avenue, Suite 240,Henderson, NV 89052, USA |
| Phone: |
+1-702-935-6300 |
| Fax: |
+1-702-260-7405 |
| E-mail: |
-
|
| Internet: |
https://www.sppirx.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
61.22% |
| IPO date: |
- |
Investor relations
| Name: |
Shiv Kapoor |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
IR@sppirx.com
|
